A staggering market valued at over $80 billion is just the beginning, as the in vitro diagnostics industry is projected to exceed $130 billion by 2030, fueled by rapid innovation and an increasing global demand for fast, accurate health information.
Key Takeaways
- The global in vitro diagnostics (IVD) market size was valued at USD 81.5 billion in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030, reaching USD 128.7 billion by 2030
- In 2023, the IVD market revenue reached approximately USD 85.06 billion, projected to expand to USD 132.20 billion by 2030 at a CAGR of 6.5%
- The IVD industry is forecasted to grow from USD 74.22 billion in 2024 to USD 109.76 billion by 2029 at a CAGR of 8.2%, driven by rising chronic diseases
- North American IVD market valued at USD 34.5 billion in 2023, holding 40.5% global share
- Europe IVD market size was USD 25.6 billion in 2022, expected to grow at 5.2% CAGR to 2030
- Asia-Pacific IVD market projected to reach USD 40.2 billion by 2030 from USD 22.1 billion in 2023 at 8.9% CAGR
- Immunoassay tests dominated IVD product segment with 41.2% share in 2023, valued at USD 35.4 billion globally
- Molecular diagnostics in IVD grew to USD 16.8 billion in 2023, holding 19.5% market share
- Clinical chemistry reagents segment accounted for 28.7% of IVD in 2022, USD 23.4 billion
- Roche Diagnostics held 15.8% global IVD market share in 2023 with revenue of USD 14.3 billion
- Abbott Laboratories IVD revenue reached USD 11.2 billion in 2023, 12.4% market share
- Siemens Healthineers Diagnostics segment USD 10.8 billion in fiscal 2023, 11.9% share
- Oncology IVD applications dominated with 24.5% market share in 2023, valued at USD 21.0 billion globally
- Infectious diseases testing in IVD generated USD 28.4 billion in 2023, 33.1% share driven by COVID and others
- Diabetes management IVD tests USD 23.1 billion in 2022, 27.8% of total IVD applications
The IVD market is growing rapidly due to rising global health demands.
Applications and Disease Areas
1Oncology IVD applications dominated with 24.5% market share in 2023, valued at USD 21.0 billion globally
Verified2Infectious diseases testing in IVD generated USD 28.4 billion in 2023, 33.1% share driven by COVID and others
Verified3Diabetes management IVD tests USD 23.1 billion in 2022, 27.8% of total IVD applications
Verified4Cardiology IVD segment valued USD 12.7 billion in 2023, 14.8% market share
Directional5Oncology companion diagnostics tests USD 6.9 billion in 2023, fastest growing at 12.4% CAGR
Single source6Autoimmune disease IVD testing USD 5.3 billion in 2022, 6.4% share with 7.2% CAGR
Verified7Nephrology IVD applications USD 4.1 billion in 2023, focused on kidney function tests
Verified8HIV diagnostics within infectious IVD USD 3.2 billion in 2023, steady demand
Verified9COVID-19 IVD tests peaked at USD 15.6 billion in 2021 but stabilized to USD 4.8 billion in 2023
Directional10Hepatitis testing IVD market USD 2.9 billion in 2023, part of infectious diseases
Single source11Thyroid disease IVD USD 2.4 billion in 2022, 8.1% CAGR projected
Verified12Sepsis diagnostics in IVD USD 1.8 billion in 2023, critical care application growth 9.5%
Verified13Genetic testing for hereditary diseases USD 7.6 billion in 2023, molecular IVD leader
Verified14Influenza diagnostics IVD USD 2.1 billion in 2022, seasonal demand
Directional15Cancer biomarker tests USD 5.7 billion in 2023, 82% of oncology IVD
Single source16Anemia diagnostics via hematology IVD USD 3.5 billion in 2023, global prevalence driver
Verified17Allergy testing IVD market USD 4.2 billion in 2022, immunoassay based
Verified18Tuberculosis diagnostics USD 1.9 billion in 2023, high in emerging markets
Verified19Cholesterol and lipid profile tests USD 6.8 billion in 2023, cardiology staple
Directional20Pharmacogenomics testing in IVD USD 2.7 billion in 2023, personalized medicine growth 14.2%
Single source21C-reactive protein (CRP) tests for inflammation USD 1.6 billion in 2022, acute care use
Verified22Prenatal screening genetic IVD USD 3.9 billion in 2023, NIPT dominant
Verified23Rheumatoid arthritis diagnostics USD 1.4 billion in 2023, autoimmune segment
Verified24Troponin tests for MI USD 2.3 billion in 2023, key cardiac biomarker
Directional25STD testing panel IVD USD 8.5 billion in 2022, infectious growth area
Single source26Alzheimer's disease IVD biomarkers emerging USD 0.9 billion in 2023, 18.7% CAGR
Verified27Vitamin D deficiency testing USD 2.0 billion in 2023, endocrinology application
Verified28Lyme disease diagnostics USD 0.7 billion in 2022, regional infectious focus
Verified29BNP/NT-proBNP heart failure tests USD 1.5 billion in 2023, cardiology IVD
DirectionalApplications and Disease Areas Interpretation
While infectious diseases may have leveraged a pandemic to claim the top revenue spot, the quieter, relentless march of cancer diagnostics has quietly built the most valuable castle in the IVD kingdom.
Key Companies and Market Share
1Roche Diagnostics held 15.8% global IVD market share in 2023 with revenue of USD 14.3 billion
Verified2Abbott Laboratories IVD revenue reached USD 11.2 billion in 2023, 12.4% market share
Verified3Siemens Healthineers Diagnostics segment USD 10.8 billion in fiscal 2023, 11.9% share
Verified4Danaher Corporation (Beckman Coulter) IVD sales USD 6.7 billion in 2023, 7.4% global share
Directional5Thermo Fisher Scientific IVD business USD 5.4 billion in 2023, holding 6.0% market share
Single source6Bio-Rad Laboratories IVD revenue USD 1.9 billion in 2023, 2.1% share focused on clinical diagnostics
Verified7Becton Dickinson (BD) diagnostics unit USD 4.2 billion in fiscal 2023, 4.6% IVD share
Verified8Ortho Clinical Diagnostics (QuidelOrtho) generated USD 2.8 billion IVD revenue in 2023, 3.1% share
Verified9bioMérieux SA IVD sales EUR 3.1 billion (USD 3.4 billion) in 2023, 3.8% global share
Directional10Sysmex Corporation diagnostics revenue JPY 450 billion (USD 3.0 billion) in fiscal 2023, 3.3% share
Single source11Hologic Inc. diagnostics division USD 2.1 billion in 2023, strong in molecular IVD 2.3% share
Verified12Qiagen NV molecular diagnostics USD 1.7 billion in 2023, 1.9% IVD market share
Verified13Illumina Inc. contributed USD 4.5 billion to IVD via NGS in 2023, 5.0% specialized share
Verified14Arkray Inc. global IVD revenue approx. USD 1.2 billion in 2023, 1.3% share in glucose monitoring
Directional15Mindray Medical diagnostics sales CNY 12.5 billion (USD 1.8 billion) in 2023, 2.0% emerging share
Single source16Snibe Diagnostic held 1.5% global IVD share with USD 1.4 billion revenue in 2023
Verified17PerkinElmer (Revvity) diagnostics USD 2.9 billion in 2023, 3.2% share post-rebrand
Verified18Fujirebio Inc. IVD revenue USD 0.8 billion in 2023, niche immunoassay leader 0.9% share
Verified19LumiraDx collapsed but held 0.5% share pre-2023 with USD 0.45 billion peak revenue
Directional20Grifols SA diagnostics division EUR 1.8 billion (USD 2.0 billion) in 2023, 2.2% share
Single source21Bio-Rad quality control systems strong, overall 2.1% IVD share USD 1.9 billion 2023
Verified22Top 10 IVD companies controlled 72% market in 2023, Roche leading at 15.8%
Verified23Abbott Alinity systems boosted share to 12.4% with USD 11.2 billion IVD sales 2023
Verified24Siemens Atellica platforms contributed to 11.9% share USD 10.8 billion revenue
Directional25Danaher life sciences IVD grew 8% YoY to USD 6.7 billion 2023 share 7.4%
Single source26Thermo Fisher Unity platforms held 6.0% with USD 5.4 billion diagnostics 2023
Verified27BD held 4.6% IVD share via BD FACSAIQ USD 4.2 billion 2023
Verified28QuidelOrtho merger boosted to 3.1% share USD 2.8 billion revenue FY2023
Verified29bioMérieux VIDAS systems 3.8% share EUR 3.1 billion sales 2023
Directional30Sysmex hematology leader 3.3% share JPY 450B revenue FY2023
Single sourceKey Companies and Market Share Interpretation
The titans of testing are in a relentless, multi-billion dollar chess match for our blood, urine, and data, where Roche sits as the current king with a 15.8% crown, yet a full quarter of the board remains a chaotic scramble for every remaining drop of market share.
Market Size and Growth
1The global in vitro diagnostics (IVD) market size was valued at USD 81.5 billion in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030, reaching USD 128.7 billion by 2030
Verified2In 2023, the IVD market revenue reached approximately USD 85.06 billion, projected to expand to USD 132.20 billion by 2030 at a CAGR of 6.5%
Verified3The IVD industry is forecasted to grow from USD 74.22 billion in 2024 to USD 109.76 billion by 2029 at a CAGR of 8.2%, driven by rising chronic diseases
Verified4North America dominated the IVD market with a 40.2% share in 2022, valued at USD 32.8 billion
Directional5The point-of-care (POC) diagnostics segment within IVD is expected to register the fastest CAGR of 7.1% from 2023 to 2030 due to demand for rapid testing
Single source6Global IVD market grew by 4.5% in 2022 post-COVID recovery, reaching USD 82.3 billion
Verified7By 2028, the IVD market is projected to hit USD 115.42 billion with a CAGR of 6.3% from 2021 base of USD 78.5 billion
Verified8The molecular diagnostics sub-market in IVD was USD 15.2 billion in 2022, expected to grow at 11.2% CAGR to 2030
Verified9IVD reagents segment accounted for 68.4% of the market revenue in 2022, valued at USD 55.7 billion globally
Directional10Emerging markets in Asia-Pacific are driving IVD growth at 7.8% CAGR from 2023-2030
Single source11The global IVD market is anticipated to reach USD 140 billion by 2032, growing at 5.7% CAGR from 2023's USD 86.4 billion
Verified12Immunoassay segment in IVD held 42% market share in 2023, valued at USD 36.1 billion
Verified13IVD market in hospitals generated USD 28.9 billion in 2022, representing 35.5% of total IVD revenue
Verified14Clinical chemistry analyzers market within IVD was USD 12.6 billion in 2023, projected CAGR 5.4% to 2030
Directional15Post-pandemic, IVD market rebounded with 6.8% growth in 2023 to USD 89.2 billion globally
Single source16The tissue diagnostics segment of IVD is expected to grow at 7.5% CAGR from 2024-2031, from USD 5.8 billion base
Verified17Global IVD consumables market size stood at USD 58.4 billion in 2022, with 6.1% CAGR forecast
Verified18By 2027, IVD market projected at USD 102.8 billion, up from USD 75.6 billion in 2020 at 5.2% CAGR
Verified19Microbiology IVD segment valued USD 8.7 billion in 2023, expected 6.9% CAGR to 2030
Directional20IVD market share of fully automated systems reached 52% in 2022, valued at USD 42.4 billion
Single source21The IVD sector saw investment of USD 4.2 billion in R&D in 2023, boosting growth projections
Verified22Point-of-care IVD market was USD 32.4 billion in 2022, forecasted CAGR 10.2% to USD 70.1 billion by 2030
Verified23Global hematology IVD market size USD 11.5 billion in 2023, 5.8% CAGR expected
Verified24IVD market in low- and middle-income countries grew 9.1% in 2023 to USD 12.3 billion
Directional25Coagulation IVD segment valued at USD 7.9 billion in 2022, 6.3% CAGR to 2030
Single source26The overall IVD market CAGR is projected at 7.4% for 2024-2032, from USD 92.1 billion base
Verified27Diabetes IVD testing market within IVD was USD 22.6 billion in 2023, 8.5% growth forecast
Verified28IVD instruments market revenue USD 26.8 billion in 2022, 4.9% CAGR expected
Verified29Next-gen sequencing in IVD diagnostics valued USD 4.3 billion in 2023, 16.7% CAGR to 2030
Directional30IVD market total revenue hit USD 90.7 billion in 2023 amid rising infectious disease testing
Single sourceMarket Size and Growth Interpretation
While everyone was worrying about the world's health, the in vitro diagnostics industry was quietly building a remarkably healthy and diverse portfolio, proving that understanding disease is a business that's both vital and vitally lucrative.
Product and Technology Segments
1Immunoassay tests dominated IVD product segment with 41.2% share in 2023, valued at USD 35.4 billion globally
Verified2Molecular diagnostics in IVD grew to USD 16.8 billion in 2023, holding 19.5% market share
Verified3Clinical chemistry reagents segment accounted for 28.7% of IVD in 2022, USD 23.4 billion
Verified4Microbiology culture media in IVD valued USD 3.9 billion in 2023, 6.2% CAGR expected
Directional5Hematology analyzers within IVD generated USD 10.2 billion in 2022, 5.6% share
Single source6Point-of-care blood glucose monitoring devices held 55% of POC IVD in 2023, USD 18.1 billion
Verified7PCR-based molecular IVD tests market USD 5.4 billion in 2023, 14.3% CAGR
Verified8Tissue diagnostics microscopes segment USD 1.2 billion in 2022, part of 7.1% growing area
Verified9Coagulation analyzers in IVD valued USD 7.1 billion in 2023, 22% of hemostasis segment
Directional10NGS-based companion diagnostics in IVD USD 2.8 billion in 2022, fastest tech growth at 17.2%
Single source11ELISA kits in immunoassay IVD accounted for 38% share in 2023, USD 13.7 billion
Verified12Fully automated immunoassay analyzers USD 6.5 billion in 2022, 9.8% CAGR
Verified13Biosensors technology in IVD POC grew to USD 4.7 billion in 2023, 11.5% share
Verified14Flow cytometry instruments in IVD USD 3.9 billion in 2022, 7.4% CAGR forecast
Directional15Mass spectrometry in IVD clinical diagnostics USD 1.8 billion in 2023, emerging at 12.1% CAGR
Single source16Lateral flow assays in IVD valued USD 8.2 billion in 2022, dominant in rapid tests
Verified17Digital PCR systems in IVD USD 1.1 billion in 2023, 15.6% growth rate
Verified18Urinalysis test strips and readers USD 2.3 billion in 2022, 5.9% of clinical chemistry
Verified19Chemiluminescence immunoassay tech held 45% of immunoassay IVD in 2023, USD 16.3 billion
Directional20Microfluidics-based IVD devices USD 3.4 billion in 2023, 13.2% CAGR
Single source21Hematology reagents market USD 5.6 billion in 2022, 52% of analyzers revenue
Verified22Companion diagnostic tests using NGS USD 4.1 billion in 2023, 18.9% CAGR projected
Verified23Western blotting in IVD protein analysis USD 0.9 billion in 2022, steady 4.8% growth
Verified24Electrochemical biosensors in IVD USD 2.1 billion in 2023, key POC tech
Directional25Hematology staining reagents USD 1.7 billion in 2022, part of core IVD consumables
Single source26Real-time PCR kits for IVD USD 4.8 billion in 2023, 10.7% share of molecular
Verified27Immunochromatographic assays USD 6.2 billion in 2022, rapid diagnostics leader
Verified28CRISPR-based IVD diagnostics emerging market USD 0.4 billion in 2023, 25.3% CAGR
Verified29Blood gas analyzers in IVD USD 1.5 billion in 2023, critical care focus
Directional30Loop-mediated isothermal amplification (LAMP) in IVD USD 0.6 billion in 2022, POC molecular growth
Single sourceProduct and Technology Segments Interpretation
While immunoassays reign supreme with a $35 billion crown, the relentless and lucrative revolution lies in the molecular trenches where NGS and CRISPR are growing at a double-digit pace, proving the real power is in reading your genetic fine print, not just your basic biochemical billboard.
Regional Insights
1North American IVD market valued at USD 34.5 billion in 2023, holding 40.5% global share
Verified2Europe IVD market size was USD 25.6 billion in 2022, expected to grow at 5.2% CAGR to 2030
Verified3Asia-Pacific IVD market projected to reach USD 40.2 billion by 2030 from USD 22.1 billion in 2023 at 8.9% CAGR
Verified4U.S. IVD market dominated with USD 30.8 billion in 2022, 39% of North America share
Directional5China IVD market grew 12.4% in 2023 to USD 15.7 billion, driven by aging population
Single source6Germany held 28% of European IVD market in 2022, valued at USD 7.2 billion
Verified7India IVD sector valued USD 4.5 billion in 2023, projected CAGR 11.2% to USD 9.8 billion by 2030
Verified8Japan IVD market size USD 8.9 billion in 2022, 4.8% CAGR forecast amid tech advancements
Verified9Latin America IVD market reached USD 5.6 billion in 2023, growing at 7.1% CAGR
Directional10Middle East & Africa IVD market valued USD 3.2 billion in 2022, 9.5% CAGR to 2030 due to infrastructure investments
Single source11U.K. IVD market was USD 4.8 billion in 2023, representing 19% of Europe total
Verified12Brazil IVD industry grew 8.3% in 2023 to USD 2.1 billion, led by private labs
Verified13South Korea IVD market size USD 3.4 billion in 2022, fastest APAC growth at 10.1% CAGR
Verified14France accounted for 15.5% of European IVD market in 2023, USD 4.0 billion revenue
Directional15Australia IVD market valued USD 1.9 billion in 2023, 6.7% CAGR projected
Single source16Russia IVD sector reached USD 2.7 billion in 2022 despite sanctions, 5.9% growth
Verified17Canada IVD market USD 3.7 billion in 2023, 12% of North America share
Verified18Saudi Arabia IVD market grew 11.2% to USD 1.2 billion in 2023 on Vision 2030 investments
Verified19Mexico IVD industry valued USD 1.8 billion in 2022, 7.8% CAGR forecast
Directional20Italy held 12.3% Europe IVD share in 2023, USD 3.2 billion
Single source21Indonesia IVD market USD 1.4 billion in 2023, 13.5% CAGR due to urbanization
Verified22Spain IVD revenue USD 2.9 billion in 2022, 5.4% growth rate
Verified23South Africa IVD market size USD 0.9 billion in 2023, 10.2% CAGR projected
Verified24U.A.E. IVD sector valued USD 0.8 billion in 2022, fastest MEA growth at 12.1%
Directional25Argentina IVD market USD 1.1 billion in 2023, challenged by economic factors but 6.9% CAGR
Single source26Thailand IVD industry grew to USD 1.6 billion in 2023, 9.8% APAC average
Verified27Netherlands IVD market USD 2.1 billion in 2022, 4.7% CAGR
Verified28Turkey IVD revenue USD 2.3 billion in 2023, 8.2% growth
Verified29Egypt IVD market valued USD 0.7 billion in 2022, 11.5% CAGR forecast
DirectionalRegional Insights Interpretation
The global IVD market reveals a stark diagnostic of its own: while North America currently writes the prescription with its dominant $34.5 billion share, the prognosis points decisively toward Asia-Pacific, whose blistering growth rate will soon have it swallowing the world's diagnostic pills.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 3MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 4MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 5STATISTAstatista.comVisit source
- Reference 6ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 7PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 8GMINSIGHTSgminsights.comVisit source
- Reference 9WHOwho.intVisit source
- Reference 10ROCHEroche.comVisit source
- Reference 11ABBOTTabbott.comVisit source
- Reference 12SIEMENS-HEALTHINEERSsiemens-healthineers.comVisit source
- Reference 13DANAHERdanaher.comVisit source
- Reference 14IRir.thermofisher.comVisit source
- Reference 15INVESTORinvestor.bio-rad.comVisit source
- Reference 16INVESTORSinvestors.bd.comVisit source
- Reference 17IRir.quidelortho.comVisit source
- Reference 18BIOMERIEUXbiomerieux.comVisit source
- Reference 19SYSMEXsysmex.co.jpVisit source
- Reference 20INVESTORSinvestors.hologic.comVisit source
- Reference 21QIAGENqiagen.comVisit source
- Reference 22INVESTORinvestor.illumina.comVisit source
- Reference 23ARKRAYarkray.co.jpVisit source
- Reference 24MINDRAYmindray.comVisit source
- Reference 25SNIBEsnibe.comVisit source
- Reference 26IRir.revvity.comVisit source
- Reference 27FUJIREBIOfujirebio.comVisit source
- Reference 28LUMIRADXlumiradx.comVisit source
- Reference 29GRIFOLSgrifols.comVisit source
- Reference 30THERMOFISHERthermofisher.comVisit source
- Reference 31BDbd.comVisit source
- Reference 32QUIDELORTHOquidelortho.comVisit source